MedImmune will cease to exist after 30 years
In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.
Archives for February 18, 2019
EMA implored to improve trial reporting, with over 50% of trials still missing results
The EMA needs to fix problems with the clinical trial registry to improve reporting across Europe, says TranspariMED founder, as seemingly small issues can “seriously hinder compliance.”
SCOPE 2019
Tech is advancing, but uncertainty creates an ‘opposing effect’ to positive movement
The industry has advanced to a point that should justify the financial investment in new technology, though uncertainty, and a lack of support, are hindering movement.
European manufacturing waiver to ‘level the playing field’
The introduction of the SPC manufacturing waiver will generate billions in export sales and create a number of jobs across the EU, suggests Medicines for Europe.
SCOPE 2019
Saama adds new AI-based capabilities to its analytics platform
Saama Technologies today unveiled three new machine learning-based capabilities, extending the functionality of its life science analytics cloud.
Lonza utilizes global network for CBD-based drug manufacture
Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
‘Simply unacceptable’: FDA warns against illegitimate opioids
The FDA issued a warning letter to McKesson for violations concerning a possible distribution of illegitimate opioid products while calling for action in securing the supply chain from illegitimate medications, especially opioids.